Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use XACDURO safely and effectively. See full prescribing information for XACDURO. XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
XACDURO is indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. Limitations of Use XACDURO is not indicated for the treatment of HABP/VABP caused by pathogens other than susceptible isolates of Acinetobacter baumannii-calcoaceticus complex [see Clinical Studies (14)]. To reduce the development of drug-resistant bacteria and maintain the effectiveness of XACDURO and other antibacterial drugs, XACDURO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
- generic_name
- sulbactam and durlobactam
- brand_name
- sulbactam, durlobactam
- product_names
- sulbactam and durlobactam, sulbactam, durlobactam
- ndc
- 68547-111, 68547-111-10, 68547-211, 68547-211-20, 68547-311, 68547-311-30
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en